Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

endometrial cancer

- PMLiVE

FDA approves argenx’s Vyvgart Hytrulo for rare neuromuscular disorder CIDP

Approximately 24,000 US patients are currently being treated for chronic inflammatory demyelinating polyneuropathy

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

- PMLiVE

Bristol Myers Squibb’s Krazati granted FDA accelerated approval in colorectal cancer

More than 106,000 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

FDA expands indication for Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys

The neuromuscular condition is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

Merck’s adult-specific pneumococcal vaccine Capvaxive granted FDA approval

The vaccine is designed to protect against the strains responsible for the majority of adult invasive pneumococcal disease

- PMLiVE

AbbVie’s IL-23 inhibitor Skyrizi approved by FDA to treat ulcerative colitis in adults

The inflammatory bowel disease affects more than one million people in the US

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

AstraZeneca’s Calquence shows survival benefit in phase 3 mantle cell lymphoma study

The rare form of non-Hodgkin lymphoma is estimated to affect more than 27,500 people globally

- PMLiVE

Merck’s Keytruda regimen granted FDA approval to treat endometrial cancer

Approximately 67,880 new cases of uterine cancer will be diagnosed in the US this year

- PMLiVE

Roche announces positive phase 3 results for Columvi combination in DLBCL

The most common form of non-Hodgkin lymphoma affects 160,000 people worldwide every year

- PMLiVE

Amgen’s Blincyto approved by FDA for new acute lymphoblastic leukaemia indication

More than 6,500 new cases of the blood cancer were diagnosed in the US last year

- PMLiVE

AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer

Mismatch repair-deficient disease accounts for up to 30% of endometrial cancer cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links